Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts (ECP Registry)
The purpose of this study is to determine if Extracorporeal Photopheresis (ECP) is effective in the treatment of progressive Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. Lung transplantation has become the treatment of choice for selected patients with end-stage lung disease. However, long-term survival after transplantation remains disappointing. Chronic rejection (bronchiolitis obliterans syndrome [BOS]) has emerged as the leading obstacle to better long-term outcomes, and represents the leading cause of death beyond the first year after transplantation. BOS is diagnosed by the decline in the FEV1 measurement from a pulmonary function test. The management of BOS has been disappointing. In general, BOS is treated by intensifying the immunosuppressive regimen. Despite treatment, most patients continue to show progressive decline in lung function resulting in worsening functional status, quality of life, and ultimately graft failure and death.
Extracorporeal Photopheresis (ECP) has been used as a salvage treatment for progressive BOS with favorable clinical results in many cases showing patient improvement. On May 2, 2012, the Center for Medicare Services issued a decision memo statin the ECP is covered for Medicare beneficiaries for the treatment of BOS following lung allograft transplantation only wehn the procedure is provided under a clinical research study. It is highly unlikely that providers that currently order ECP for their BOS patients who have already failed optimized immunosuppressive drug therapy would be willing to randomize half of their patients to continue on their failed drug therapy.What is not well understood at this time, however, is whether certain coexisting disease states or patient-related demographic, functional, treatment-related or diagnostic variables might prove to have predictive value in identifying subsets of BOS patients that are likely, or unlikely, to experience reduced rate of decline or stabilization in FEV1 following ECP treatment. This is a Registry study to enroll 160 patients from multiple U.S. centers to (1) confirm that ECP significantly reduces the rate of FEV1 decline in BOS patients refractory to standard immunosuppressive drug therapy, and (2) capture and assess specified patient demographic, treatment-related, diagnostic, functional and co-morbidity- related variables that may predict outcomes after ECP therapy.
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration:||1 Year|
|Official Title:||Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts|
- Change in the rate of FEV1 decline assessed by comparing the average rate of FEV1 decline over the 6 months prior to ECP against the average rate of FEV1 decline over the 6 months following initiation of ECP [ Time Frame: 1 year ]The study will prospectively capture FEV1 through spirometry during the course of ECP therapy and out to one year in accordance with the following schedule: Days 0, 30, 60, 90, 120,150, 180, 240, 300 and 365. Spirometry from Day 0 through Day 120 may be performed within 7 days to accommodate patient/provider scheduling needs, and generally will coincide with a scheduled ECP treatment. Spirometry from Day 150 through Day 365 may be per formed within 14 days to meet patient/provider scheduling needs.
- Average rate of FEV1 decline over the 12 months following initiation of ECP [ Time Frame: 12 months ]The study will prospectively capture FEV1 through spirometry during the course of ECP therapy and out to one year in accordance with the following schedule: Days 0, 30, 60, 90, 120,150, 180, 240, 300 and 365. Spirometry from Day 0 through Day 120 may be performed within 7 days to accommodate patient/provider scheduling needs, and generally will coin cide with a scheduled ECP treatment. Spirometry from Day 150 through Day 365 may be per formed within 14 days to meet patient/provider scheduling needs.
- All-cause mortality at 12 months following initiation of ECP [ Time Frame: 12 months ]Observational only
- Proportion of patients with treatment related serious adverse events [ Time Frame: 12 months ]
A Serious Adverse Event is any adverse event that results in death, a life-threatening adverse experience, a persistent or significant disability/incapacity, inpatient hospitalization or prolongation of existing hospitalization, emergency department visit or activation of an acute response team, pregnancy abortion, or a congenital anomaly, birth defect, or cancer in a neonate/infant born to a female subject. Medical events that do not strictly fulfill these criteria should be considered SAEs if they seriously jeopardize the subject or require aggressive medical or surgical intervention to prevent one of the above outcomes.
Patients will be monitored and followed clinically according to each site's standard clinical practice. Sites should follow their local IRB's guidelines in terms of reporting AEs and SAEs to the local IRB
|Study Start Date:||January 2015|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||July 2018 (Final data collection date for primary outcome measure)|
|prospective single-arm cohort.||
Procedure ECP Treatments will be performed using Therakos UVAR XTS system or the Therakos CELLEX system
There is evidence to support that ECP benefits these patients, but we don't know how to predict which patients will benefit most. Patients will will be identified by physician investigators and co-investigators, and study staff, and through review of relevant administrative databases that are maintained for routine clinical care purposes (e.g. lung transplantation division database, pulmonary function laboratory database, etc.), subject to local IRB approval. Once eligibility is confirmed and the patient is provided informed consent, the patient will be assigned a unique case number created from the electronic data base. The patient demographics, co-morbidities, medical history including date of lung transplantation, underlying disease necessitating lung transplantation, vital signs, height , weight, and current medication regimen, maintenance immunosuppression and any changes in medication should be entered on the electronic case report forms. All FEV1 measurements captured within the 6 months prior to enrollment should be entered in the electronic case report forms.Certain source documents will be required and verified on all forms electronically submitted. Necessary source documents will be clearly requested on the electronic case report forms.
Patients should receive 24 ECP treatments over the 6-month period following enrollment, in accordance with the following schedule:
- 8 to 10 treatments over the first 30 days following treatment initiation;
- 8 to 10 treatments in the next 60 days (months 2 and 3);
- 6 treatments in the next 90 days (months 4 through 6) at a rate of 2 treatments per month.
During ECP, blood is taken from the body through a standard venous catheter and the cells are separated by centrifugation via a specialized pheresis machine. The machine treats the blood with an agent called methoxsalen that becomes active when exposed to an ultraviolet light inside the machine. This changes the white blood cells to better enable them to reduce rejection and better suppress BOS. The machine then returns the blood into the patient through the catheter. .
An improvement in the FEV1 measurement taken from the pulmonary function test will be used to assess the success or the benefit of the ECP treatment. Patient's will have spirometry the first week of therapy, Day 30, 60, 90, 120, 150, 180, 240, 300, and at one year.
Statistical Methods -Based on a 95% power analysis and assuming a 5% loss to follow-up of enrolled patients, 160 patients will need to be enrolled to detect at least a 50% reduction in the rate of FEV1 decline at one-year follow-up. A 50% decrease in the rate of FEV1 decline can importantly extend survival and improve the opportunity to receive a new lung allograft, as well as delay time to onset of severe physical limitations. Our power analysis was based on findings from our previously published 60 patient series. Specifically, we first calculated values that reflected the difference between pre-intervention and post-intervention FEV1 slope values. The corresponding values for standard deviation of slope differences were adjusted for possible greater variability in the post-treatment period in this study. These values for derived slope differences (50% of 87 ml/month) and corresponding standard deviation values (150) were then used to calculate required enrollment using a treatment effect of 50% reduction of FEV1 decline and using a power of 95%. This analysis, with 5% late loss, indicates a required enrollment of 160 patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02181257
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35226|
|United States, California|
|University of California San Diego|
|La Jolla, California, United States, 92093|
|United States, Indiana|
|Indiana University Health|
|Indianapolis, Indiana, United States, 46202|
|United States, Iowa|
|University of Iowa|
|Iowa City, Iowa, United States, 52242|
|United States, Michigan|
|University of Michigan Health System|
|Ann Arbor, Michigan, United States, 48109|
|United States, Minnesota|
|University of Minnesota Medical Center, Fairview|
|Minneapolis, Minnesota, United States, 55455|
|United States, Missouri|
|Washington University School of Medicine|
|St. Louis, Missouri, United States, 63110|
|United States, New York|
|New York, New York, United States, 10032|
|United States, Ohio|
|The Cleveland Clinic|
|Cleveland, Ohio, United States, 44195|
|United States, Pennsylvania|
|University of Pittsburgh|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||George J. Despotis, M.D.||Washington University St. Louis School of Medicine|